David Munn, MDDavid Munn, MD

Professor, Pediatric Oncology
Co-Director, Pediatric Immunotherapy Program
Medical College of Georgia at Augusta University

Research Summary

Our research is focused on activating the body’s own immune system to fight cancer. We work on discovering the ways in which cancers suppress the immune system, and on identifying the molecular mechanisms that tumors use to escape from immune attack. Along with our collaborators, we have developed new drugs and clinical strategies to activate the immune response against tumors and enlist the patients’ own immune system to enhance the effectiveness of conventional chemotherapy drugs and radiation. Target diseases include adult and pediatric solid tumors and brain tumors. Dr. Munn’s research is funded by the National Institutes of Health and support from charitable foundation donors.Research.com Badge for Research Honor

Research Focus

Our research is focused on tumor immunology and the molecular mechanisms of immune suppression and tolerance in the tumor microenvironment. The laboratory studies the regulation of anti-tumor T cell activation by tolerogenic dendritic cells and regulatory T cells (Tregs) in the setting of cancer.

Major focus areas in the laboratory include (i) activation of suppressive tumor-associated Tregs via the indoleamine 2,3-dioxygenase (IDO) pathway; (ii) regulation of the dendritic cell (DC) population in tumors and the choice between tolerogenic vs. immunogenic DCs; and (iii) tolerance-induction to dying tumor cells mediated via the enzyme indoleamine 2,3-dioxygenase (IDO) and the Bruton’s Tyrosine Kinase (BTK) pathway. 

Contact Us

The David Munn Lab

Health Sciences Campus

Georgia Cancer Center - M. Bert Storey Research Building

1410 Laney Walker Blvd., CN-4141, Augusta, GA 30912

(706) 721-7141

(706) 721-4804


Research Interests

Basic-science studies of the role of the indoleamine 2,3-dioxygenase pathway in Tregs, including the regulation of the suppressor phenotype vs. destabilization and reprogramming during inflammation.  The translational goal of these studies is to develop orally-bioavailable small-molecule inhibitors drugs to block this novel immune-checkpoint and destabilize Tregs in tumors.

Molecular mechanisms of inflammation-induced differentiation of immunogenic dendritic cells, and the suppression of immunogenic DCs by IDO-activated Tregs.   The translational goal of these studies is to develop orally-bioavailable small-molecule drugs that induce differentiation of immunogenic DCs in tumors.

Basic and pre-clinical studies of immune response to dying tumor cells after chemotherapy; and synergy between conventional chemotherapy and novel forms of immunotherapy targeting Tregs and DCs.

Design and immune-monitoring of Phase I and Phase II clinical trials of IDO-inhibitor drugs in combination with chemotherapy, radiation and BTK-inhibitor drugs.  These include first-in-children pediatric trials, in conjunction with the Pediatric Immunotherapy Service and Dr. Theodore Johnson.

Research Team

photo of Joyce Wilson

Joyce Wilson

  • Research Associate
photo of Anita Sharma, PhD

Anita Sharma, PhD

  • Research Associate

(706) 721-8749

photo of Gabriela Pacholczyk

Gabriela Pacholczyk

  • Research Associate

(706) 721-8748

photo of Zuzana Berrong, PhD

Zuzana Berrong, PhD

  • Postdoctoral Fellow

(706) 721-8749